Table 3.
Base-case results
| Patient’s selection strategy |
LYs | Discounted QALYs |
Discounted Cost (€) |
LYs gained |
QALYs gained |
Incremental cost (€) |
ICER (€/LYG) |
ICER (€/QALY) |
|---|---|---|---|---|---|---|---|---|
| Telaprevir IL-28B-guided triple therapy | ||||||||
| F3–F4 | 23.27 | 14.15 | €39 922.17 | – | – | – | – | – |
| F2–F4 | 24.48 | 14.73 | €42 115.49 | 1.21 | 0.58 | €2193.33 | €1800.11 | €3798.43 |
| F1–F4 | 24.76 | 14.86 | €43.549.14 | 1.49 | 0.71 | €3626.97 | €2426.62 | €5132.13 |
| Boceprevir RVR-guided therapy | ||||||||
| F3–F4 | 22.73 | 13.89 | €36 681.69 | – | – | – | – | – |
| F2–F4 | 23.95 | 14.46 | €40 091.19 | 1.22 | 0.57 | €3409.49 | €2798.91 | €5944.90 |
| F1–F4 | 24.14 | 14.56 | €41 366.78 | 1.41 | 0.67 | €4685.08 | €3326.88 | €7042.49 |
F3–F4, Metavir fibrosis stage 3 and 4; F2–F4, Metavir fibrosis stage 2, 3 and 4; F1–F4, Metavir fibrosis stage 1, 2, 3 and 4; LYs, life years; QALYS, quality-adjusted life years; ICER, incremental cost-effectiveness ratio; RVR, rapid virologic response.